Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 1900 of 2529 entries
View as:

Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)

Phase: N/A Priority: Normal
NCT ID: NCT01392326 Org: User:
Start: 09/30/11 End: 10/31/14 Due: 10/31/15

A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia

Phase: N/A Priority: Normal
NCT ID: NCT03025698 Org: User:
Start: 09/30/17 End: 01/27/25 Due: 01/27/26

Study Assessed the Safety and Efficacy of Eltrombopag in Chinese Refractory or Relapsed Severe Aplastic Anemia (SAA) Subjects.

Phase: N/A Priority: Normal
NCT ID: NCT03988608 Org: User:
Start: 12/09/19 End: 05/17/23 Due: 05/17/24

Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Phase: N/A Priority: Normal
NCT ID: NCT01604278 Org: User:
Start: 05/31/12 End: 01/31/13 Due: 01/31/14

Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in France

Phase: N/A Priority: Normal
NCT ID: NCT06092879 Org: User:
Start: 03/06/24 End: 12/15/26 Due: 12/15/27

French Study to Highlight the Unmet Treatment Needs of 3L+ CP-CML and With T315I-mutated CML Patients

Phase: N/A Priority: Normal
NCT ID: NCT05619978 Org: User:
Start: 05/03/21 End: 10/29/21 Due: 10/29/22

BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia

Phase: N/A Priority: Normal
NCT ID: NCT01669174 Org: User:
Start: 09/30/12 End: 12/31/14 Due: 12/31/15

Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase

Phase: N/A Priority: Normal
NCT ID: NCT00905593 Org: User:
Start: 09/30/08 End: - Due: -

A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03499899 Org: User:
Start: 07/02/18 End: 11/24/21 Due: 11/24/22

Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)

Phase: N/A Priority: Normal
NCT ID: NCT04792567 Org: User:
Start: 04/19/21 End: 08/15/22 Due: 08/15/23

Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation

Phase: N/A Priority: Normal
NCT ID: NCT04666259 Org: User:
Start: 05/25/21 End: 06/26/24 Due: 06/26/25

Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

Phase: N/A Priority: Normal
NCT ID: NCT01173731 Org: User:
Start: 10/31/10 End: 10/31/13 Due: 10/31/14

A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02829723 Org: User:
Start: 10/21/16 End: 12/01/22 Due: 12/01/23

Pharmacokinetics of BAF312 in Patients With Hepatic Impairment

Phase: N/A Priority: Normal
NCT ID: NCT01565902 Org: User:
Start: 10/31/12 End: 03/31/14 Due: 03/31/15

Octreotide Efficacy and Safety in First-line Acromegalic Patients

Phase: N/A Priority: Normal
NCT ID: NCT00171886 Org: User:
Start: 07/31/02 End: 05/31/06 Due: 05/31/07

A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.

Phase: N/A Priority: Normal
NCT ID: NCT01124864 Org: User:
Start: 10/31/10 End: 08/31/14 Due: 08/31/15

Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00699296 Org: User:
Start: 05/31/08 End: - Due: -

ACZ885 in Type 1 Diabetes Mellitus

Phase: N/A Priority: Normal
NCT ID: NCT01322321 Org: User:
Start: 03/31/11 End: - Due: -

Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)

Phase: N/A Priority: Normal
NCT ID: NCT01242774 Org: User:
Start: 10/31/10 End: 05/31/14 Due: 05/31/15

Efficacy and Safety of FTY720 Versus Mycophenolate Mofetil (MMF, Roche Brand) in de Novo Adult Renal Transplant Recipients

Phase: N/A Priority: Normal
NCT ID: NCT00239863 Org: User:
Start: 05/31/04 End: - Due: -

Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients

Phase: N/A Priority: Normal
NCT ID: NCT03876769 Org: User:
Start: 06/24/19 End: 10/19/27 Due: 10/19/28

Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02294786 Org: User:
Start: 12/17/14 End: 10/19/17 Due: 10/19/18

A Prospective, Multicenter Study on Best Clinical Use of Imatinib in the Advanced Gastrointestinal Stromal Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00940563 Org: User:
Start: 03/31/02 End: - Due: -

Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs

Phase: N/A Priority: Normal
NCT ID: NCT01263353 Org: User:
Start: 11/30/10 End: 03/31/14 Due: 03/31/15

A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Hepatic Impairment Compared With Matched Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT05753592 Org: User:
Start: 10/31/22 End: 12/17/23 Due: 12/17/24